24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Blame Diabetes: Rates of 2 Nerve Conditions on the RiseElectronic Messaging Intervention Cuts Cardiovascular Risk in T2DMHealth Tip: Preventing Diabetic Foot SoresEarly Menopause May Be Tied to Type 2 DiabetesMore Than 100 Million Americans Have Diabetes or Prediabetes: CDCNT-proBNP Improves Heart Failure Prediction in T2DMStem Cell Educator Therapy May Help Fight DiabetesResistance Training Improves Microvascular Blood Flow in T2DMNew Diabetes Treatment Teaches Rogue Immune Cells to BehaveIncreased Parental Anxiety With Increased Diabetes RiskIntensive Lifestyle Changes May Up Frailty Fracture Risk in DMExercising Safely With DiabetesHyperbaric Oxygen Therapy Increasingly Being UsedTherapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 PercentT1DM Patients With Active β-Cell Function Differ ImmunologicallyMany People With Type 1 Diabetes Still Make Some InsulinTryptophan May Be Marker for Diabetic NephropathyEstimated Prevalence of Diabetes 10.9 Percent in ChinaReview Spotlights Optimal Care of T2DM + OsteoporosissRAGE Linked to Risk of Incident Diabetic NephropathyDiabetic Ketoacidosis Poses Fetal Risk During/After EventFDA Warns Diabetics Against Use of Secondhand Test StripsRisk of Cardiovascular Events Similar With, Without DiabetesPCSK9 Increased in Females, Youth With Type 1 DiabetesText Messaging Intervention Can Up Glycemic Control in T2DMGood Results for Zone MPC-Based Artificial PancreasBroccoli Extract Shows Promise for Type 2 DiabetesSleep Apnea Linked to Diabetic Retinopathy in Type 2 DiabetesADA: Canagliflozin Tied to Lower Risk of Cardiovascular EventsKey Diabetes Test Gives Higher Blood Sugar Readings in Black PatientsFor Diabetics, Nasal Powder Fixed Severe Low Blood SugarADA: Glucose Self-Monitoring Often Lacks Benefit in T2DMCan Folks With Type 2 Diabetes Forgo the Finger Stick?Sitagliptin Stimulates Distal Tubular Natriuresis in T2DMStudy Confirms Link Between Diabetes Med and Rare But Dangerous ComplicationLower HbA1c Linked to Better Diabetes-Specific HRQoL in YouthHealth Tip: What's My Target Blood Glucose?Comorbid Celiac Disease Common Among Youth With T1DMDiabetic Foot Ulcers, Infections Significantly Up Burden of CareMapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas Feasible
Links
Related Topics

Medical Disorders

Increased Use of Newer Meds for Diabetic Nephropathy in the U.S.


HealthDay News
Updated: Mar 27th 2017

new article illustration

MONDAY, March 27, 2017 (HealthDay News) -- From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with diabetic nephropathy, according to a study published online March 15 in the Journal of Clinical Pharmacy and Therapeutics.

Using the IMS Health's National Disease and Therapeutic Index, Oyintayo Ajiboye, M.D., M.P.H., and Jodi B. Segal, M.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, analyzed medication prescription patterns for six classes of medications among patients with diabetic nephropathy.

The researchers observed an increase in the number of annual office visits, from 772,860 in 2010 to 1,868,618 in 2013, followed by a decrease to 830,596 in 2014. Of the four classes of diabetes medications included in the study, the most frequently used were sulfonylureas and DPP-4 inhibitors. Use of DDP-4 inhibitors gradually increased; by the last quarter of 2014 they were used in 54 percent of treatment visits. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were prescribed in most treatment visits across these years, with peaks above 90 percent, although there were some periods when their use was low.

"Future studies should assess if the utilization of these medications continues to increase over time and should generate more evidence on the factors affecting the different treatment options so that more focused interventions can be done to improve patient outcomes," the authors write.

Abstract
Full Text (subscription or payment may be required)